PRESS: Fortune — Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market.
Learn more

Decoding biology to radically improve lives

Recursion was founded more than a decade ago on the idea that we could take images of cells and use these images to train artificial intelligence to understand the vast unknown biological space – the cellular disruptions driving disease – to reduce the massive 90% failure rate of traditional drug discovery.

Our mission

AI Enabled Drug Discovery and Development, at scale

explore our pipeline

AI Enabled Drug Discovery and Development, at scale

explore our pipeline

Better medicines, through novel insights and precision design

We’re using data and AI to bring better medicines to patients, faster.



The Recursion OS has yielded an advanced pipeline of potential first-in-class and best-in-class treatments for conditions with high unmet need including aggressive cancers and rare diseases. Today, we’ve demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages.

Explore our pipeline

3 key ingredients: data, models, and compute

Over the last decade, we have built one of the largest fit-for-purpose proprietary biological and chemical datasets in the world — 65 petabytes spanning phenomics, transcriptomics, InVivomics, proteomics, ADME, and de-identified patient data. Our automated wet lab utilizes robotics and computer vision to capture millions of cell experiments per week — enabling us to quickly make and test novel discoveries. All of our results feed back into our platform – the Recursion Operating System – in a continuously improving feedback loop.

Our data and the Recursion OS enable us to train intelligent machine learning models for drug discovery and development, which help us rapidly identify new targets and design highly optimized molecules that fuel our pipeline of potential first-in-class and best-in-class medicines.

To process all this data, we worked with NVIDIA to build biopharma’s most powerful supercomputer: BioHive-2.

Explore our technology

The latest from Recursion

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Read more →

Leveraging the Power of Patient Data in AI Drug Discovery

Read more →

Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market

Read more →
© 2025 Recursion. All rights reserved.